SANGRIX (SGRX) Financials
Ticker history: BTOG became SGRX (Sangrix Inc.) on . Earlier news and filings retain their original names and dates. View BTOG history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2026, filed Sep 18, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SGRX SEC filings page.
This page shows SANGRIX INC. (SGRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest figures show a loss-making business whose balance sheet expanded sharply while liabilities grew faster than assets.
From FY2025 to FY2026, total liabilities rose3147.1% while assets rose498.3% ; the balance-sheet expansion was financed disproportionately through obligations rather than matching asset growth.
The FY2026 net loss was
The current ratio was 7.0x, while the liquidity measure equaled 6.4 months of the latest annual operating outflow; short-term coverage therefore differs from the broader financing picture. At FY2026 year-end, liabilities were
Financial Health Signals
SANGRIX INC. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
SANGRIX INC. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
SANGRIX INC. reported a net loss of $14.3M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
SANGRIX INC. reported a net loss of $14.3M in fiscal year 2026. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Cash & Balance Sheet
SANGRIX INC. held $1.6M in cash as of fiscal year 2026; no long-term debt figure is on record for that period.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Margins & Returns
SANGRIX INC.'s ROE was -254.2% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 141.7 percentage points from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Capital Allocation
None of these metrics is reported for fiscal year 2026.
SGRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $39K-98.6% | $2.9M-53.9% | $6.3M0.0% | $6.3M-92.2% | $80.5M+232.0% | $24.2M-75.5% | $99.1M-2.0% | $101.1M+59.8% | $63.3M |
| Cost of Revenue | N/A | N/A | $3.8M-64.6% | $10.8M0.0% | $10.8M-86.0% | $77.5M+248.8% | $22.2M-75.4% | $90.4M-1.1% | $91.5M+57.1% | $58.2M |
| Gross Profit | N/A | $39Kn/m | -$945Kn/m | -$4.6Mn/m | -$4.6M-252.3% | $3.0M+47.7% | $2.0M-76.5% | $8.7M-10.4% | $9.7M+90.5% | $5.1M |
| SG&A Expenses | $2.8M-10.7% | $3.1M-19.2% | $3.8M+30.9% | $2.9M0.0% | $2.9M+59.8% | $1.8M-29.2% | $2.6M+142.6% | $1.1M-37.2% | $1.7M+23.3% | $1.4M |
| Operating Income | -$14.3Mn/m | -$3.0Mn/m | -$14.8Mn/m | -$28.3Mn/m | -$28.3Mn/m | -$3.5Mn/m | -$3.4Mn/m | -$511K-107.3% | $7.0M+100.0% | $3.5M |
| EBITDA | N/A | -$3.0Mn/m | -$13.9Mn/m | -$22.9M | N/A | N/A | N/A | $178K-97.6% | $7.6M+87.1% | $4.1M |
| Interest Expense | N/A | $665K+11.7% | $596K+162.0% | $227K0.0% | $227K+45.7% | $156K+26.7% | $123K-83.1% | $731K-43.0% | $1.3M+92.0% | $668K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | -$1.0M-549.1% | $223K+4.5% | $214K-70.1% | $714K-18.4% | $876K |
| Net Income | -$14.3Mn/m | -$4.4Mn/m | -$17.5Mn/m | -$28.2M-971.0% | $3.2Mn/m | -$45.6Mn/m | -$4.9M-211.8% | $4.4M+15.8% | $3.8M+53.5% | $2.5M |
| EPS (Basic) | -$70.43 | -$0.08 | -$1003.41 | -$8.61 | -$8.61n/m | -$3.29 | -$0.18-185.7% | $0.21+10.5% | $0.19+58.3% | $0.12 |
| EPS (Diluted) | -$70.43 | -$84.84 | -$1003.41 | -$8.61 | -$8.61n/m | -$3.29 | -$0.18-185.7% | $0.21+10.5% | $0.19+58.3% | $0.12 |
| Diluted Shares (Avg) | 339,699 | 77,016 | 17,472 | 3M | 3M+196.3% | 1M | 22M+7.0% | 21M+4.3% | 20M+0.4% | 20M |
Not reported in any period shown, so not listed: R&D Expenses.
SGRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.2M+498.3% | $3.5M-47.1% | $6.7M-49.9% | $13.3M-61.8% | $35.0M-14.5% | $40.9M-35.5% | $63.3M+23.4% | $51.4M+52.2% | $33.7M | N/A |
| Current Assets | $10.2M+187.5% | $3.5M-47.1% | $6.7M+87.1% | $3.6M-85.1% | $23.9M-26.4% | $32.5M-35.3% | $50.3M+10.0% | $45.7M+57.3% | $29.0M | N/A |
| Cash & Equivalents | $1.6M+2720.8% | $56K-96.1% | $1.4M+8558.4% | $16K-8.6% | $18K+816.4% | $2K-99.8% | $1.1M-60.1% | $2.7M+741.3% | $319K+1382.1% | $22K |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Inventory | N/A | N/A | N/A | N/A | N/A | $229Kn/m | $0-100.0% | $113K+4029.1% | $3K | N/A |
| Accounts Receivable | N/A | N/A | $117Kn/m | $0n/m | $0-100.0% | $11.1M+13.3% | $9.8M-75.1% | $39.5M+62.2% | $24.4M | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0-100.0% | $2.4M-20.3% | $3.0Mn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $5.2Mn/m | $0 | N/A | N/A |
| Total Liabilities | $12.1M+3147.1% | $372K-93.6% | $5.8M+87.8% | $3.1M+925.0% | $300K-99.3% | $42.5M+16.4% | $36.5M+36.1% | $26.8M+49.9% | $17.9M | N/A |
| Current Liabilities | $1.5M+291.6% | $372K-85.1% | $2.5M-3.8% | $2.6M+762.9% | $300K-99.2% | $38.7M+18.2% | $32.7M+43.4% | $22.8M+35.0% | $16.9M | N/A |
| Non-Current Liabilities | $10.6Mn/m | $0-100.0% | $3.3M+575.3% | $486Kn/m | $0-100.0% | $3.8M+0.3% | $3.8M-5.3% | $4.0M+307.3% | $982K | N/A |
| Total Equity | $5.6M+44.1% | $3.9M+134.6% | $1.7M-83.8% | $10.3M-70.4% | $34.7Mn/m | -$3.2M-113.5% | $23.8M-2.9% | $24.5M+74.8% | $14.0M+38.5% | $10.1M |
Not reported in any period shown, so not listed: Long-Term Debt, Retained Earnings.
SGRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9Mn/m | -$2.3Mn/m | -$7.9Mn/m | -$6.8Mn/m | -$14.2Mn/m | -$10.4Mn/m | -$5.9Mn/m | -$5.3Mn/m | -$3.6Mn/m | -$2.5M |
| Depreciation & Amortization | N/A | $0-100.0% | $901K-83.2% | $5.4M | N/A | N/A | N/A | $690K+27.2% | $542K+2.0% | $532K |
| Stock-Based Compensation | N/A | N/A | $73K+8.9% | $67K-95.9% | $1.6M-14.1% | $1.9M+103.1% | $930Kn/m | $0n/m | $0 | N/A |
| Capital Expenditures | N/A | N/A | N/A | $115K-98.6% | $8.3M | N/A | $700K+3294.2% | $21K-76.9% | $89K+665.4% | $12K |
| Free Cash Flow | N/A | N/A | N/A | -$6.9Mn/m | -$22.5M | N/A | -$6.6Mn/m | -$5.3Mn/m | -$3.7Mn/m | -$2.5M |
| Investing Cash Flow | -$200K-112.9% | $1.5M+51.1% | $1.0M-76.0% | $4.3Mn/m | -$11.3Mn/m | $0-100.0% | $159K-86.7% | $1.2Mn/m | -$89Kn/m | -$12K |
| Financing Cash Flow | $4.6Mn/m | -$609K-107.3% | $8.3M+233.2% | $2.5M-90.4% | $25.9M+205.2% | $8.5M+108.4% | $4.1M-38.7% | $6.7M+66.6% | $4.0M+59.9% | $2.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SGRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2620-F | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 100.0%+132.7pp | -32.7%+40.2pp | -72.9%0.0pp | -72.9%-76.6pp | 3.7%-4.7pp | 8.4%-0.4pp | 8.7%-0.8pp | 9.6%+1.5pp | 8.0% |
| Operating Margin | N/A | -7574.9% | -513.6% | -452.1% | -452.1% | -4.3%+9.9pp | -14.2%-13.7pp | -0.5%-7.5pp | 7.0%+1.4pp | 5.6% |
| Net Margin | N/A | -11108.2% | -607.0% | -450.7% | 51.7%+108.4pp | -56.7%-36.5pp | -20.1%-24.5pp | 4.4%+0.7pp | 3.7%-0.2pp | 3.9% |
| Return on Equity | -254.2%-141.7pp | -112.5%+942.0pp | -1054.4%-779.5pp | -275.0%-284.3pp | 9.3% | N/A | -20.5%-38.3pp | 17.8%-9.1pp | 26.9%+2.6pp | 24.2% |
| Return on Assets | -67.5%+56.5pp | -124.1%+138.2pp | -262.3%-50.7pp | -211.6%-220.9pp | 9.3%+120.8pp | -111.6%-103.9pp | -7.7%-16.2pp | 8.5%-2.7pp | 11.2% | N/A |
| Current Ratio | 6.98-2.5x | 9.50+6.8x | 2.68+1.3x | 1.38-78.4x | 79.77+78.9x | 0.84-0.7x | 1.54-0.5x | 2.00+0.3x | 1.72 | N/A |
| Liabilities-to-Equity | 2.15+2.1x | 0.10-3.4x | 3.47+3.2x | 0.30+0.3x | 0.01 | N/A | 1.53+0.4x | 1.09-0.2x | 1.28 | N/A |
| Asset Turnover | N/A | 0.01-0.4x | 0.430.0x | 0.47+0.3x | 0.18-1.8x | 1.97+1.6x | 0.38-1.5x | 1.93-1.1x | 3.00 | N/A |
| FCF Margin | N/A | N/A | N/A | -109.8% | -360.0% | N/A | -27.3%-21.9pp | -5.3%-1.7pp | -3.6%+0.3pp | -4.0% |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Where SANGRIX INC. Ranks
Frequently Asked Questions
Is SANGRIX INC. profitable?
No, SANGRIX INC. (SGRX) reported a net loss of $14.3M in fiscal year 2026.
What is SANGRIX INC.'s return on equity (ROE)?
SANGRIX INC. (SGRX) has a return on equity of -254.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is SANGRIX INC.'s operating cash flow?
SANGRIX INC. (SGRX) recorded an outflow of $2.9M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are SANGRIX INC.'s total assets?
SANGRIX INC. (SGRX) had $21.2M in total assets as of fiscal year 2026, including both current and long-term assets.
What is SANGRIX INC.'s current ratio?
SANGRIX INC. (SGRX) had a current ratio of 6.98 as of fiscal year 2026, which is generally considered healthy.
What is SANGRIX INC.'s liabilities-to-equity ratio?
SANGRIX INC. (SGRX) had a liabilities-to-equity ratio of 2.15 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
What is SANGRIX INC.'s return on assets (ROA)?
SANGRIX INC. (SGRX) had a return on assets of -67.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is SANGRIX INC.'s P/E ratio?
SANGRIX INC. (SGRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $757K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is SANGRIX INC.'s price-to-sales ratio?
SANGRIX INC. (SGRX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $757K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does SANGRIX INC.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, SANGRIX INC. (SGRX) held $1.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.9M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is SANGRIX INC.'s Piotroski F-Score?
SANGRIX INC. (SGRX) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are SANGRIX INC.'s earnings high quality?
SANGRIX INC. (SGRX) reported a net loss of $14.3M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.